Tags Posts tagged with "Vitality Biopharma"

Vitality Biopharma

0 1831

Vitality Biopharma (VBIO) To Present Today!

 

Today’s the day that Vitality Biopharma (VBIO) will be presenting at the Ninth Annual Biotech Showcase 2017 Conference. Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

This being one of the most active weeks in biotech has been highlighted by many large outlets as San Francisco has now become a city within a city for biotech investors and companies. We’ve seen VBIO have a much stronger week this week as compared to last and after closing last Thursday near its weekly lows, VBIO saw early signs of a rally on Friday (1-6).

This has continued into this week and the latest coverage that cannabis biotech could receive during this pivotal week could shed more light on companies like VBIO & their novel therapies. After seeing 2 week highs of $3.36 yesterday, we’ll be watching today to see what the reaction may be from the company’s presentation.

 


Click Here To View Full VBIO Report

 


 

 

$VPRB Announces The Launch Of Their Premier Product The Kush Army Knife

 

VPR Brands, LP and Kush Army Knives, LLC is proud to announce the launch of their premier product with its unique and proprietary multi-faceted product known as the Kush Army Knife, the ultimate cannabis multi-tool. This item is anticipated to be one of the top selling accessories within the cannabis sector in 2017. Developed in conjunction with VPR Brands who helped redesign, refine, and bring to market the final prototype the product will be making initial deliveries in late January.

The Kush Army Knife is…

 


Click Here To View Full Release


 

 

Restrictions With Legal Marijuana Threaten Industry’s Reform

 

Cannabis recently became legal for adults in the state of Nevada. However, farming it is illegal unless they live more than 25 miles away from a retail marijuana shop. This is an example of what’s called a “halo rule.” Marijuana Policy Project introduced this idea in the 2010 Proposition 203 that brought medical marijuana to Arizona.

It mandated that any patient living within 25 miles of a dispensary could not grow their own marijuana. They would have to register with and purchase their cannabis from their local authorized dispensary. At first, this meant that all patients could grow their own cannabis, as the law went into effect before any licenses had been awarded to dispensaries. However, as the dispensaries opened, every patient within that 1,964 square mile area had to remove their marijuana crops.

 


Click Here To View Full Article

 


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 30 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $15,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. We may buy or sell additional shares of (VPRB,VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 2977

Biotech Buzz Could Focus On Cannabis

San Francisco will be a hotbed for biotechnology this week. The annual JPMorgan Healthcare Conference kicks off on Monday the 9th and goes through Thursday the 12th. But this isn’t the only conference and there will surely be thousands of investors in the city to attend all kinds of presentations being made, which are focused on biotechnology & healthcare. Outside of just JPM’s conference, the crowd around Union Square also consists of the Biotech Showcase, which sets up at the Hilton San Francisco Union Square; and the OneMedForum across Post Street from the St. Francis.

Biotech_Showcase

There’s also the StartUp Health Festival on Montgomery Street and other conferences. Considering that thousands of people who aren’t going to invitation-only conferences like JPM, it would stand to reason that attention will be on the industry in full force this week.

Recently Vitality Biopharma (VBIO) announced that it would be presenting at the Biotech Showcase on Wednesday January 11th. The Showcase hosts over 2,800 attendees, over 5,600 one-on-one meetings, and will be expecting to see over 550 investors present.

Biotech Showcase™ is an investor and networking conference working to provide private and public biotech and life sciences companies with an opportunity to present to, and engage with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this week, which is widely viewed as setting the tone for the coming year…so JPMorgan is just the tip of the iceberg during San Fran’s biotech invasion.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.

We said that this week could shed some light on many biotech companies including those involved with cannabis. Now we see that VBIO will be at ground zero, not just as another biotech company that could benefit from the shockwave but management will be in the exact location and presenting to the exact audiences.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2457
marijuana

 

What To Watch With Vitality Biopharma ($VBIO)

 

Vitality Biopharma (VBIO) is staying at the top of our list this week. We’ve witnessed first-hand how strong of a run that this has had and continues to have. Over the last few days we’ve seen VBIO hold a tend above $2.50, where last week it saw a trend in the higher $1 range. In fact since last week, VBIO is trending more than 30% higher than those previous lows. Keep in mind that within the last few weeks VBIO has hit highs of $4.23 so as many of you have already witnessed, this has been capable of dynamic breakouts over shorter periods of time.

This is all happening as the company continues to make progress with their novel therapies. has been going by route of prodrugs. Their unique approach targets CB2 receptors and can be taken orally to directly target specific tissues or organs. Right now, the company is working to create therapies for Crohn’s disease patients and those who suffer from inflammatory bowel disease. VBIO has filed intellectual property applications and is seeking worldwide patent protection through 2035, with strong composition of matter claims for its prodrugs.

In fact, the company’s novel use of certain developmental therapies have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. And if you remember, they’ve also just received the Drug Enforcement Administration’s approval for its pharma development facility…something that not many of its competitors (if any) can say right now especially in the current climate. Looking for more on VBIO?

 


Click Here To View Full VBIO Report



Things To Expect After Medical Cannabis Is Legal In Florida

Dr. Joseph Dorn was the medical director of Surterra Therapeutics, which is one of six distributing locations that are licensed to dispense medical marijuana in the state of Florida. The constitutional amendment allows higher-strength cannabis to be used for a broader range of medical conditions. However, the true measure of what the amendment means won’t be seen immediately until a new set of rules are carried out by the State’s Legislature.


Click Here To View Full Article


 

#ICYMI: Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

 

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.

 


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 904

 

Vitality Biopharma ($VBIO)’s 3-Day Rally Set To Continue?

Vitality Biopharma (VBIO) saw a very strong run during most of December. When we first began to pick up coverage it was sitting around $0.98 and during the course of the weeks to follow, we watched as VBIO ran to highs of $4.23. Despite the fact that many thought the excitement was over when VBIO pulled back, we’ve now seen it breakout once again. In fact since bottoming at $1.93 last week, VBIO has maintained a 3 day run that has taken it back to highs of $3.22 yesterday; a 67% rebound.

We said it late last year and the sentiment continues to hold up so far in 2017: Canna-biotech companies have begun to catch much more attention; biotech over all has begun to see an increase in activity following President Elect Trump coming into the spotlight. In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%. This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were recetnly reviewed and approved by the U.S. FDA. So, if is your first time seeing VBIO, we’ve got a full report you can access before the opening bell today.

 


Click Here To View Full VBIO Report



The Hero of HOLLYWEED

 

In case you missed it this New Years the citizens and tourists got a wonderful welcome when they looked up at Mount Lee in HollyWood, or should we say “HOLLYWEED!” The Iconic Hollywood sign was given a hilarious, yet impactful redesign given that the state of California now has recreational marijuana after a November 8th vote in favor of the law change by its illustrious citizens.

 


Click Here To View Full Article


 

Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.


Click Here To View Full Article



Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 6083

Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

Approval of cannaboside pharmaceutical research included review by FDA and California Research Advisory Panel

LOS ANGELES, CA–(Marketwired – Dec 21, 2016) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel which permits the Company to scale up activities at its facilities used for the development of novel cannabinoid pharmaceutical prodrugs.

Vitality has been working with the DEA to ensure adequate on-site measures are in place to prevent diversion of Schedule I controlled substances. As a component of this process, Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were reviewed and approved by the U.S. Food & Drug Administration (FDA). The California Research Advisory Panel, a part of the California Attorney General’s Office, has also granted Vitality a research permit to conduct cannabinoid pharmaceutical development activities that are designed to enable regulatory approval of first-in-man clinical trials.

Despite cannabis attaining legal status within the State of California and in many other states across the U.S. for medical and recreational purposes, pharmaceutical research and development continues to be closely regulated by the DEA and FDA. Vitality’s work is focused on developing a novel class of THC and CBD prodrugs that reduce or avoid psychoactive side effects through targeted prodrug technology.

“We are excited to scale up our research and to aggressively pursue clinical testing of our compounds, and this approval greenlights that work,” said Dr. Brandon Zipp, Director of R&D, and Scientific Co-founder of Vitality Biopharma. Robert Brooke, the Company’s CEO, further states that, “There are surprisingly few companies in the United States that are properly licensed and developing differentiated cannabinoid pharmaceutical products. We are very proud of our team’s work to enable this milestone, and believe that recent discoveries have provided us with a very unique opportunity.”

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CONTACT INFORMATION
Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio

 

 


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

    0 1930

    Vitality Biopharma, Inc. (VBIO):

    Technical Update

     

    We’re heading into a new week and continue to keep Vitality Biopharma Inc. (VBIO) in our main spotlight. Canna-biotech has been something we’ve reported on in detail and VBIO is heavily involved within the space.

    Over the last few weeks, we’ve highlighted several key points about the company and the potential of the market but what could be even more exciting is the technical pattern that could be developing:

    There are a lot of technical indicators flashing on this chart that could be catalysts for a continuation trend as VBIO keeps pressing to break upper resistance levels on its chart.

    Granted that since we’ve begun covering the company, VBIO has managed to climb roughly 50%. Even with this being the case, there has been a noticeable level of resistance around the $1.45-$1.47 area on the chart to where there could be a potential short squeeze scenario in the making.

    VBIO has seen a significant jump in momentum over the last few weeks. Since we alerted it, we’ve now seen our newest cannabis biotech feature rally to highs of $1.47 so far. Keep in mind that we picked up coverage on this company just as it was hitting a bottom during a pull-back period. Prior to this VBIO was trading as high as $1.84 during more recent months & as high as $2.25 during the summer. So if this is your first time seeing VBIO in brief, check out the full report here:

    The Future Of Cannabis Biotech:
    Connecting The Dots

    As always, if you have any questions for us, don’t hesitate to reach out. We try to respond as quickly as possible to everyone’s request and if you’re new to trading, don’t forget to check out our intro videos HERE.


     


     

     

     





     

      12 28215

      The Future of Cannabis Biotech

      With some of the most successful fund managers in the world believing a Trump Presidency will benefit the biotech industry more than any other sector and legalization of both recreational and medical cannabis quickly spreading across the country, we feel it’s absolutely necessary to have cannabis biotech in your portfolio right now. Todd Hagopian, the most successful biotech fund manager in the market today, has even said he thinks the entire biotechnology market is about to double.

      That is why we feel there couldn’t be a better time to introduce our readers to Vitality Biopharma (VBIO). This emerging cannabis biotech company is rapidly gaining investor interest while focusing on the treatment of inflammatory bowel disease, narcotic bowel syndrome, and multiple sclerosis. Furthermore, the Company’s proprietary glycosylation technology for producing cannabinoid prodrugs could, in fact, revolutionize the entire cannabis biotech industry and change how CBD treatments are administered to patients. Steering the ship at the forefront of this technology are two biotech experts who already built two highly successful NASDAQ biotech companies.

      But before we get into VBIO’s veteran management team, let’s take a look at a type of technology that could mold the future of cannabis biotech.

      Potential Game-Changing Technology

      Vitality Biopharma recently announced they had developed a new class of cannabinoid prodrugs, known as cannabosides. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues like harsh side effects. Early independent trial results show that VBIO’s technology could change how all current CBD treatments are administered.

      VBIO’s cannabosides are more stable and soluble than regular cannabinoids, meaning there is less risk of non-psychotropic cannabidiol (CBD) being converted to psychotropic THC or otherwise being degraded or diluted in the acidic stomach environment. Upon ingestion, these cannabosides can enable the selective delivery of THC and CBD to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits without having THC enter the bloodstream. For example, a prodrug could target a specific tissue or organ, such as the brain or gut, giving the patient better results with far less side effects.

      In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.

      As of 2015, there were approximately 15 prodrugs classified as blockbusters, meaning they had annual sales exceeding $1billion.

      Vitality Bio creates the cannaboside prodrugs through enzymatic glycosylation, a process perfected in 2015. Management believes that glycosylation of cannabinoids can improve product bioavailability, eliminate unwanted side effects, and be useful in any medical treatment where oral CBD is administered at a high dose. Independent studies have already demonstrated reliable and improved targeting to specific tissue/organs upon oral delivery of GBD glycoside prodrugs vs. active CBD.

      The Company’s goal is to ultimately provide a compelling oral cannabinoid pharmaceutical that physicians will be eager to prescribe and patients will prefer.

      VBIO Compared to the Competition

      Many synthetic cannabinoids on the market today are poorly soluble. GW Pharma’s (GWPH) two leading products, Epidiolex® and Sativex® are solutions. Sativex is a mixture of CBD/THC solubilized with 50% v/v alcohol (ethanol) into an oral spray. Although the alcohol volume is small, it can still cause problems for alcoholics, pregnant women, and young children. Oral lesions may also form in users of alcohol-based cannabis sprays, coupled with reported stinging, bad taste, and dry mouth. Sativex also contains propylene glycol, which may cause further irritation and dry mouth. The product must be stored in the refrigerator and has a shelf life of only 42 days. An oral capsule cannaboside prodrug developed by VBIO may alleviate many of these problems.

      Other companies, such as Zynerba Pharmaceuticals (ZYNE), are developing cannabinoid transdermal patches. Transdermal delivery routes can in some cases lead to hives/skin irritation, and typically deliver relatively small drug dosages. Oral cannaboside capsules avoid this problem and could enable far more convenient delivery of cannabinoids in a form that is fast-acting and that works at a high dose for maximal effect.

      We believe prodrug development like VBIO’s cannabosides is the future of the medical cannabis industry.

      Now, let’s make one thing clear. We are not saying that GW Pharma or Zynerba have poor drug treatments. What we are saying is that we believe VBIO’s technology could make them far better.

      Creating prodrugs is already a commercially validated strategy used by big pharma companies to improve drug efficacy and reduce side effects in non-cannabis related drugs. And because the reference drug or original drug already has independent verification and/or approval of its safety and efficacy, the prodrug can be approved much quicker by simply demonstrating similar safety and efficacy as the original. At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin (acetylsalicylic acid), a synthetic prodrug of salicylic acid.

      It comes down to this…

      Cannabis biotech is still a very young industry, infant you could even say. And just like how the pharmaceutical industry matured and advanced using prodrug formulations of existing drugs to achieve higher efficacy and less side effects, the cannabis biotech industry will follow the same path. Drugs like GWPH’s Sativex and Epidiolex may be some of the first drugs to hit the market but that doesn’t mean they are the best, or even the best version of themselves. It is often times the prodrug variation of an approved drug that surpasses the $1billion annual sales mark; like we saw with Aspirin, the prodrug of salicylic acid.

      VBIO Drug Pipeline

      Through its glycosylation technology, Vitality Bio has produced more than 25 novel cannabosides and has patent applications pending that include composition of matter claims for prodrugs of cannabinoids that have been studied extensively in clinical trials worldwide, including THC, CBD, and cannabidivarin (CBDV).

      VBIO’s IP portfolio includes 79 patent claims and almost 200 individual compounds,

      including novel glycoside prodrugs of the most abundant phytocannabinoids, THC and CBD, as well as a variety of other phytocannabinoids and endocannabinoids.

      The company aims to develop and receive approval for these proprietary molecules as pharmaceuticals by taking advantage of the more efficient FDA review and approval process that is available for prodrugs. This greatly reduces the need for large and expensive clinical trials. Because clinical studies have already been performed or are currently still in process for many large commercial indications such as epilepsy, neuropathic pain, multiple sclerosis, inflammatory bowel disease, schizophrenia, and Huntington’s disease, management aims to create improved prodrug formulations of these cannabinoids that ultimately deliver a superior product.

      Vitality Biopharma’s two main drugs are moving towards beginning Phase I/Phase II studies in 2017.

      • VB100 – Inflammatory Bowel Disease, Narcotic Bowel Syndrome
      • VB210 – Neuropathic Pain, Irritable Bowel Syndrome, Opiate-induced Bowel Dysfunction, Muscle Spasticity in Multiple Sclerosis

      “Independent clinical trials have shown VBIO’s prodrugs retain almost all of the benefits of cannabinoids and, furthermore, they can be approved by the FDA at a far lower cost and on an accelerated timeline.” – according to Insider Financial Magazine

      With the current state of the biotech and cannabis markets, we feel it is important for investors to familiarize themselves with VBIO right now. The value and growth opportunities with biotech investments are before they start announcing potentially positive data from Phase I/Phase II/Phase III clinical trials. That is because positive study data and trial results tend to significantly increase biotech company stock prices. It is not uncommon for a biotech company’s stock to go up 100% or even 300% in a single trading day after announcing such data.

      Strong Management from Successful NASDAQ Biotech Companies

      CEO – Robert Brooke

      Mr. Brooke is a biomedical engineer and experienced biotech entrepreneur. He was the founder of a drug development company that became Lion Biotechnologies (NASDAQ: LBIO) in 2013. He also co-founded Intervene Immune. Mr. Brooke also had a successful hedge fund stint as an analyst for Bristol Capital, responsible for more than 50 direct healthcare investments.

      Chairman & Co-Founder – Avtar Dhillon, MD

      Mr. Dhillon has extensive biotech experience. He is currently Chairman of three biotech companies: Inovio Pharmaceuticals (NASDAQ: INO), Oncosec Medical (NASDAQ: ONCS) and Arch Therapeutics (ARTH). He has also raised over $200 million in public markets to ensure that his companies have sufficient research funding that is critical to a biotech company’s success. Mr. Dhillon is also a former venture capitalist and family physician for more than 10 years.

      Director of Research and Development, Scientific Co-Founder – Brandon Zipp, PhD

      Dr. Zipp is a scientist with over 10 years of research experience with glucosyltransferase enzymes – the enzymes used in VBIO’s proprietary development process. He has a Ph.D Biochemistry and Molecular Biology from the University of California, Davis.

      We always say you invest in management. And what we mean by that is no matter how great a company’s product or technology is, you need a capable management team to properly bring it to market. A cure for cancer in a lab does a company and its shareholders no good if the management team cannot commercialize the drug and bring it to market. Companies will encounter several financial hurdles and operational speed bumps along the way. A good management team can overcome these obstacles while staying focused on their goal and progressing through their business plan, in turn, building shareholder value. This is why it is important to invest in companies with proven and successful management teams.

      Conclusion

      The medical marijuana and cannabis industry is booming. And the biotech industry is poised for a massive bull run with Donald Trump winning the election. Right now could be the perfect time to add cannabis biotech to your portfolio.

      What was hype and speculation only a few years ago is now an investable market with tremendous upside. At the center of the industry is biopharma R&D being pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Just as prodrug development advanced the non-cannabis pharmaceutical market, we expect similar technology to help mature an infant biotech cannabis industry.

      Vitality Bio is currently conducting preclinical studies in anticipation of filing IND applications in 2017 for glycosylated cannabinoid products called cannabosides. The most advanced candidate is VB100, a cannaboside prodrug under development for the acute management of inflammatory bowel disease. A second candidate, VB210, is under development for chronic conditions that affect both the GI and CNS. With a strong IP portfolio of 79 patent claims on over 200 compounds and a proven, successful management team, VBIO could be set up to benefit from an overall cannabis biotech rally and is already quickly gaining investor interest.

       

       

       

       

       

       

       

       

       

       


      Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

      Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

      We are your #1 source for all things Marijuana Stocks, Subscribe Below!

      Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
      Ad Placements